ArticleOncotarget2018

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development.

Juan J Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.